IntroductionPharmacogenomics (PGx) is an emerging medicines optimization tool that may support efficacy and safety relating to antipsychotic prescribing. Despite growing drug-gene evidence linked to antipsychotic response, how PGx could be implemented within Early Intervention in Psychosis (EIP) services, including the views of staff, service users, and carers remains underexplored.MethodsSemi-structured interviews with service users (n = 12), and online focus groups with EIP staff (n = 18), and